Cancer

RheumNow Podcast square

Best Rheumatologists (7.19.2024)

Jack Cush, MD

This week on the RheumNow Podcast, Dr. Jack Cush reviews the news and journal reports of interesting, including irAE, pollution and Psoriasis, microwave therapy, scleroderma without scleroderma that only the best rheumatologists could discern.

Read Article
JAK inhibitors have been used as adjunctive therapy to reduce flammation arising with checkpoint inhibitor use in cancer (Hodgkins, Lung CA), using itacitinib w/ pembrolizumab or ruxolitinib & nivolumab improved trial outcomes https://t.co/eF6wO72D80 https://t.co/IFDYuI71X5

Links:

Dr. John Cush @RheumNow( View Tweet )
RheumNow Podcast square

Future Big BiTEs (6.28.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal articles and regulatory announcements from the past week on RheumNow.com.

Read Article
Lit. cohort analysis of >330K #AS shows higher risk of cancer (RR=1.16: 1.07–1.26); w/ higher risk in Asia, but not Europe. Increased CA risk for : bone (RR 3.41), thyroid(1.76), myeloma (1.74), leukemia (1.52), kidney (1.45), prostate (1.43), NHL (1.42) https://t.co/disRefur0l https://t.co/ffjED0Ftvc

Links:

Dr. John Cush @RheumNow( View Tweet )
EULAR24,Roundup

EULAR 2024 Rheumatology Roundup (6.21.2024)

Jack Cush, MD

Drs. Artie Kavanaugh and Jack Cush discuss highlights from the EULAR 2024 meeting in Vienna

Read Article
Convention1.jpg

EULAR 2024 – Day 4 Report

Jack Cush, MD

The final day of EULAR 2024 was rich in posters, Late-breaking oral presentations and EULAR updates and recommendations.  Below is a synopsis of the half-day's action.

Read Article
ACRmtg.jpg (keep)

EULAR 2024 – Day 3 Report

Jack Cush, MD

EULAR treats its attendees to a wonderful lunch each day – Schnitzel, gnocchi, goulash at lunch after muffins and coffee in the morning. It's no wonder the meeting has been a lively one, well attended with a wealth of stimulating ideas, research and discussion. Here are a few of my favorite

Read Article
important session worth reading the full recommendations - TNF tick of approval @RheumNow #EULAR2024 https://t.co/ORDocVie11

Links:

Peter Nash @drpnash( View Tweet )
Swedish/Danish cohort study in PsA 17000+ bionaïve 8000+ TNFi & 2000+ other MoA Overall non melanoma skin cancer rate 651 (505 BCC & 87 SCC) TNFi treated pts: HR 1.25 NMSC vs. bionaive (95CI 1.04 to 1.50) HR 1.19 NMSC vs. other MoA (ns) #EULAR2024 @RheumNow AbstOP0150 https://t.co/DVj8l7yFR6

Links:

Aurelie Najm @AurelieRheumo( View Tweet )
Top 3 messages Re #JAKi #safety Shared decision w benefit/risk info Some #CV risks are more Impt than others- stratify your pt into risk categories #Smoking is a big risk for #MACE & #malignancy-So work on facilitating Smoking #cessation #EULAR2024 @eular_org @RheumNow

Janet Pope @Janetbirdope( View Tweet )

Medicare & Optum claims data study of 2851 #RA pts w/ breast cancer (BC). In 3 mos before BC 27028% received bDMARDs. W/in 1st 3 yrs post-BC Dx 24-26% were receiving bDMARDs. 70% of RA pts on steroids without change w/ time https://t.co/51NcXv0xyc https://t.co/461NZiFvDO

Links:

Dr. John Cush @RheumNow( View Tweet )
RheumNow Podcast square

Is Cannabis Safe? (6.7.2024)

Jack Cush, MD

Dr. Jack Cush reviews FDA approval, news and journal articles -- and it’s the week before EULAR 2024 in Vienna!!

Read Article
Chinese study of 552 pts w/ ANCA Assoc. Vasculitis - 23 had cancer prior to AAV Dx; 43 after Dx (w/in 4.3yrs)= SIR: 2.24. CA mostly lung CA (SIR: 5), followed by kidney, bladder, ureter, prostate. Higher risk if male (HR:2.8) and older (per year, HR:1.04) https://t.co/xhH3uU3GCj

Links:

Dr. John Cush @RheumNow( View Tweet )

RheumNow Podcast square

The Window of Opportunity (5.24.2024)

Jack Cush, MD

Dr. Jack Cush reviews the journal reports and news from the past week on RheumNow.com. This week: blockbuster drugs, opioids in rheumatology and nontreatment of inflammatory arthritis?

Read Article
RheumNow Podcast square

Featured BSR Abstracts (5.2.2024)

Jack Cush, MD

Dr. Jack Cush muses on the news, journal reports, FDA announcements and the 2024 BSR abstracts just released.

Read Article
Danish registry study shows positive association between maternal autoimmune Dz & childhood cancer. AID assoc w/ all child CA (OR=1.25), ALL (1.52), Burkitts (2.69), CNS tumors (1.45). RA mothers AID had higher risk of all cancers (OR=2.1) https://t.co/EYHyHzOboc https://t.co/FNRrvySI8P

Links:

Dr. John Cush @RheumNow( View Tweet )
RheumNow Podcast square

Naysayers & Disrupters (3.22.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week - including a few contrary reports on infection, seropositivity and plasmapheresis.

Read Article
RheumNow Podcast square

Ides of March (3.15.2024)

Jack Cush, MD

Dr. Jack Cush has advice for Caesar and the superstitious, and covers pregnancy, platelets, dialysis and vaccinations in Lupus.





  1. Dutch study of 586 RA pts on bDMARDs found more nonserious infections (NSIE) (77/100PYs) than serious infx (SIE)(1.3/100Pys). Upper respiratory

Read Article
DANBIO #RA registry study: in 21,982 Rx starts (96K PtYrs) saw 1423 cancers w/ no overall increase in cancer risk with tocilizumab, sarilumab, abatacept, or rituximab (HRs from 0.7–1.1). No diff betw ABA vs TNFi (HR 1.41) nor HEME CA RTX vs TNFi (HR 0.09) https://t.co/mIEqALnnwI https://t.co/N1v3TzuBGm

Links:

Dr. John Cush @RheumNow( View Tweet )
H. Pylori is usually acquired during childhood, remains dormant until activated years later. Is assoc w/ PUD and gastric cancer, not dyspepsia. Baylor Univ Grand Round By Dr. Byron Cryer @BCryer https://t.co/KXZfigVYX9
Dr. John Cush @RheumNow( View Tweet )
"In solid tumors, treat your RA patient as if they do not have a cancer, meaning do not change your therapy if the patient is responding well. Things may get dicey if hematologic malignancy." @RheumNow #RWCS24 I work w/ my onc team to ensure the patient has the needed support.

Dr. Rachel Tate @uptoTate( View Tweet )

Danish registries study shows maternal Autoimmune Dzs (all) were assoc w/ incr risk of childhood cancers (OR=1.25, 95% CI 1.06, 1.47), acute lymphoblastic leukemia (OR =1.52), Burkitt lymphoma (OR=2.6) & CNS tumors (OR=1.45); same seen for RA mothers https://t.co/HQO972ch9R https://t.co/dDEJUo8unq

Links:

Dr. John Cush @RheumNow( View Tweet )
Cancer and Myositis #RNL2024 @RheumNow @DrLisaCS on Cancer screening: Risk stratify: dermatomyositis, NXP2, TIFy, <40yo, refractory, dysphagia, cutaneous necrosis at higher risk Enhanced risk stratification for those at risks, versus "basic screening" for lower risks https://t.co/3yy9Fx1pk8

Links:

Eric Dein @ericdeinmd( View Tweet )
JAK toxicity of interest. Eric Ruderman #RNL2024 @RheumNow https://t.co/qdlJFKTUR8

Links:

Nouf Al hemmadi @NoufAhmedAlham2( View Tweet )
While NSAID use has been assoc w/ lower risk of cancers (CNS, breast, esophageal, gastric, head & neck, hepatocellular, cholangiocarcinoma, colorectal, endometrial, lung, ovary, prostate, pancreatic); NSAIDs should not be used to prevent cancers https://t.co/YcsU7x7iy0 https://t.co/QJjHqjnuEo

Links:

Dr. John Cush @RheumNow( View Tweet )

Recent Blogs

Hard Conversations: DMARDs and Malignancy

Michael Putman, MD, MSCI
Risk Option Decision
Cancer is the most difficult DMARD risk to discuss with patients. Few warnings could scare people away from a drug faster than the words “may increase risk of cancer,” yet the risks (even when substantiated) have all been low and may be counterbalanced by the benefits of disease control. Read Post

A Brief History of Rheumatoid Arthritis Mimics

Robert Schoen, MD, MBA
books history
Imagine that 100 years from now, your great granddaughter, an eminent rheumatologist, reviews the history of rheumatoid arthritis mimics. Read Post

Featured Video

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.